ATE235918T1 - Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen - Google Patents

Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen

Info

Publication number
ATE235918T1
ATE235918T1 AT98925873T AT98925873T ATE235918T1 AT E235918 T1 ATE235918 T1 AT E235918T1 AT 98925873 T AT98925873 T AT 98925873T AT 98925873 T AT98925873 T AT 98925873T AT E235918 T1 ATE235918 T1 AT E235918T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
side effects
acid derivative
antitumor activity
Prior art date
Application number
AT98925873T
Other languages
English (en)
Inventor
Balazs Suemegi
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of ATE235918T1 publication Critical patent/ATE235918T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98925873T 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen ATE235918T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative

Publications (1)

Publication Number Publication Date
ATE235918T1 true ATE235918T1 (de) 2003-04-15

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925873T ATE235918T1 (de) 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen

Country Status (24)

Country Link
US (4) US6440998B1 (de)
EP (1) EP0993304B1 (de)
JP (1) JP2002508762A (de)
KR (1) KR20010020496A (de)
CN (1) CN1127984C (de)
AT (1) ATE235918T1 (de)
AU (1) AU735922B2 (de)
BR (1) BR9810312A (de)
CA (1) CA2294913C (de)
CZ (1) CZ298468B6 (de)
DE (1) DE69812949T2 (de)
DK (1) DK0993304T3 (de)
ES (1) ES2195344T3 (de)
HU (1) HU9701081D0 (de)
IL (1) IL133508A (de)
NO (1) NO322206B1 (de)
NZ (1) NZ502039A (de)
PL (1) PL191718B1 (de)
PT (1) PT993304E (de)
RU (2) RU2254129C2 (de)
SK (1) SK282877B6 (de)
TR (1) TR199903214T2 (de)
UA (1) UA64757C2 (de)
WO (1) WO1998058676A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (de) * 2007-03-29 2015-05-06 Wyeth LLC Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
WO2009092892A2 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN104447746A (zh) * 2013-09-18 2015-03-25 华安医学股份有限公司 一种活化ampk的化合物及其用途
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
RO118000B1 (ro) * 1993-03-31 2002-12-30 Merck & Co Inc Metoda pentru tratamentul sida, prevenirea si tratamentul infectiei cu hiv sau inhibarea proteazei hiv si compozitie farmaceutica pentru aplicarea metodei
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
US6720337B2 (en) 2004-04-13
WO1998058676A1 (en) 1998-12-30
PL337719A1 (en) 2000-08-28
US20020147213A1 (en) 2002-10-10
CN1263471A (zh) 2000-08-16
DE69812949T2 (de) 2004-02-05
IL133508A0 (en) 2001-04-30
HU9701081D0 (en) 1997-08-28
US6838469B2 (en) 2005-01-04
AU7783798A (en) 1999-01-04
US6656955B2 (en) 2003-12-02
EP0993304B1 (de) 2003-04-02
HK1029941A1 (en) 2001-04-20
UA64757C2 (uk) 2004-03-15
CZ462599A3 (cs) 2000-05-17
EP0993304A1 (de) 2000-04-19
BR9810312A (pt) 2000-09-19
TR199903214T2 (xx) 2000-12-21
RU2254129C2 (ru) 2005-06-20
CZ298468B6 (cs) 2007-10-10
RU2214238C2 (ru) 2003-10-20
CA2294913C (en) 2008-12-16
JP2002508762A (ja) 2002-03-19
NZ502039A (en) 2002-03-28
NO996349D0 (no) 1999-12-20
DK0993304T3 (da) 2003-07-28
NO996349L (no) 2000-02-23
US20030050345A1 (en) 2003-03-13
CN1127984C (zh) 2003-11-19
SK176499A3 (en) 2000-09-12
KR20010020496A (ko) 2001-03-15
PL191718B1 (pl) 2006-06-30
PT993304E (pt) 2003-08-29
DE69812949D1 (de) 2003-05-08
US20030069270A1 (en) 2003-04-10
IL133508A (en) 2005-11-20
NO322206B1 (no) 2006-08-28
AU735922B2 (en) 2001-07-19
US6440998B1 (en) 2002-08-27
SK282877B6 (sk) 2003-01-09
ES2195344T3 (es) 2003-12-01
CA2294913A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ATE235918T1 (de) Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
TNSN97211A1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
NO970894L (no) Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse
FI973518A7 (fi) Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
EP0620004A4 (de) Medizinische zusammensetzung.
JP2000159790A5 (de)
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
PL346764A1 (en) New oral formulation for 5-ht4
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2347750A1 (en) Pharmaceutical composition containing decursin
EP0974352A4 (de) Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
TR200002766T2 (tr) 3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri
TR200002767T2 (tr) Makrolit LHRH Antagonistleri
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0993304

Country of ref document: EP

REN Ceased due to non-payment of the annual fee